Shenzhen Weiguang Biological Products Co Ltd
002880
Company Profile
Business description
Shenzhen Weiguang Biological Products Co Ltd is the pharmaceutical company. It is mainly engaged in the research and development, production and sales of blood products. The company's products portfolio includes human albumin, intravenous immunoglobulin (pH4), lyophilized human immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, tetanus Human immunoglobulin, histamine human immunoglobulin, human fibrinogen, a total of 21 varieties of 21 specifications.
Contact
Guangming Street
No. 3402, Guangqiao Avenue
Guangming New District
Guangdong Province
Guangming518107
CHNT: +86 75527402880
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
859
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 7.50 | -0.08% |
| CAC 40 | 8,147.26 | 78.64 | 0.97% |
| DAX 40 | 24,269.94 | 83.45 | 0.35% |
| Dow JONES (US) | 48,587.93 | 129.88 | 0.27% |
| FTSE 100 | 9,743.53 | 94.50 | 0.98% |
| HKSE | 25,628.88 | 347.91 | -1.34% |
| NASDAQ | 23,252.92 | 57.75 | 0.25% |
| Nikkei 225 | 50,168.11 | 668.44 | -1.31% |
| NZX 50 Index | 13,408.14 | 1.23 | 0.01% |
| S&P 500 | 6,846.19 | 18.78 | 0.28% |
| S&P/ASX 200 | 8,635.00 | 8.90 | -0.10% |
| SSE Composite Index | 3,867.92 | 21.42 | -0.55% |